Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2016

NHS England has advised CCGs that a prescription for the treatment of infrequent constipation should not routinely be offered in primary care as the condition is appropriate for self-care. The NHS England guidance applies to short term, infrequent constipation caused by changes in lifestyle or diet such as lack of water or movement or changes in diet. GPs should continue to prescribe laxatives to manage acute constipation with more complex aetiology (e.g. iatrogenic) and chronic constipation.

The NHS England guidance does not apply to the management of children and laxatives for children should continue to be prescribed by GPs.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2017
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease

N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - November - 2022
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted

Guidance on consensus approaches to managing Palliative Care Symptoms

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 19 - July - 2022
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Licensed: Rheumatoid arthritis; ulcerative colitis, Crohn’s disease in adults and children
Unlicensed: Sero-negative spondyloarthropathy including psoriatic arthritis and psoriasis.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2016

Trans-anal Irrigation Systems are recommended for use within the Lancashire Health Economy for the treatment of Neurogenic Bowel Dysfunction and Non-Neurogenic Bowel Dysfunction including; chronic constipation and chronic faecal incontinence

**This Guideline is currently under review. For further information please click here**